<DOC>
	<DOCNO>NCT00479297</DOCNO>
	<brief_summary>To assess safety tolerability ascend single oral dos SAM-531 , investigational drug , healthy Japanese male subject . Secondary : To obtain preliminary pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile SAM-531 healthy Japanese male subject .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Pharmacokinetics , Pharmacodynamics SAM-531 Healthy Japanese Males</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Men age 20 45 year ( inclusive ) time get informed consent . Body mass index ( BMI ) range 17.6 26.4 kg/m2 body weight â‰¥50 kg ( BMI = [ weight ( kg ) ] / [ height ( ) 2 ) . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , digital 12lead electrocardiogram ( ECG ) . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , creatinine level must within upper limit normal eligibility . Exclusion criteria Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . Any clinically important deviation normal limit physical examination , vital sign , digital 12lead ECGs , clinical laboratory test result . Consumption caffeinecontaining product ( e.g. , coffee , tea , chocolate , soda ) alcoholic beverage prohibit 48 hour consumption grapefruit grapefruitcontaining product prohibit 72 hour study day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>